Accellta

Accellta Ltd. is a company based in Haifa, Israel, specializing in the development of technologies for stem cell culture aimed at improving affordability and quality. Founded in 2012, Accellta leverages over 15 years of research from the Stem Cell Center at the Technion’s Rappaport Faculty of Medicine. The company offers innovative solutions for the mass production of human embryonic and induced pluripotent stem cells, as well as progenitors and differentiated cells, which are essential for drug discovery, regenerative medicine, and research. Accellta's proprietary technologies, including its products Maxells and Singles, facilitate custom solutions for directed differentiation of pluripotent stem cells. In addition to its advanced media formulations, the company maintains a manufacturing facility to support the industrial production of cells, thus enabling clinicians to achieve cost-effective genetic manipulation with improved uniformity and purity.